UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000011822
Receipt number R000013817
Scientific Title Characterization of Features on MRI findings of Neuromyelitis Optica (NMO)
Date of disclosure of the study information 2013/10/01
Last modified on 2020/09/25 09:38:34

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Characterization of Features on MRI findings of Neuromyelitis Optica (NMO)

Acronym

Characterization of Features on MRI findings of Neuromyelitis Optica (NMO)

Scientific Title

Characterization of Features on MRI findings of Neuromyelitis Optica (NMO)

Scientific Title:Acronym

Characterization of Features on MRI findings of Neuromyelitis Optica (NMO)

Region

Japan


Condition

Condition

Neuromyelitis Optica (NMO)

Classification by specialty

Radiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine MR findings of the optic nerves, spinal cord, and brain in NMO patients and determine the characteristic features of NMO by comparing them with MR findings of the optic nerves, spinal cord, and brain in MS patients.

Basic objectives2

Others

Basic objectives -Others

Contribution to the differential diagnosis of NMO and MS

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Descriptive assessments of lesions in the optic nerves, spinal cord, and brain in terms of distribution, frequency, and nature in the NMO group and in the MS group.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

NMO (including NMO spectrum disorder) and MS patients who underwent MRI examination(>1.5T) from April 1,2008 by March 31, 2013

Key exclusion criteria

Patients judged by the (sub-) investigator to be ineligible as a study subject

Target sample size

200


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yukio Miki

Organization

Osaka City University

Division name

Radiology

Zip code


Address

1-4-3, Asahimachi, Abeno-ku, Osaka ,545-0051, JAPAN

TEL

06-6645-3831

Email

yukio.miki@med.osaka-cu.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yukio Miki

Organization

Osaka City University

Division name

Radiology

Zip code


Address

1-4-3, Asahimachi, Abeno-ku, Osaka ,545-0051, JAPAN

TEL

06-6645-3831

Homepage URL


Email

yukio.miki@med.osaka-cu.ac.jp


Sponsor or person

Institute

Osaka City University

Institute

Department

Personal name



Funding Source

Organization

Bayer Yakuhin, Inc.

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 10 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2013 Year 04 Month 04 Day

Date of IRB

2015 Year 07 Month 28 Day

Anticipated trial start date

2013 Year 07 Month 01 Day

Last follow-up date

2015 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

NMO is relatively prevalent in East Asia, including Japan, and magnetic resonance (MR) findings of NMO have been reported in Japan and South Korea. However, almost all reports thus far published are nothing but compilations of a relatively small number of cases at a single center.


Management information

Registered date

2013 Year 09 Month 20 Day

Last modified on

2020 Year 09 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013817


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name